XML 45 R45.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Fair Value Measurement (Details 1) (CyDex, USD $) In Millions, unless otherwise specified | 12 Months Ended
--- | ---
Dec. 31, 2014 | Dec. 31, 2013
Credit Derivatives [Line Items] |  |  |  |
Amount Of revenue for contingent consideration | 15lgnd_AmountOfRevenueForContingentConsideration |  |  |
Contingent Consideration |  |  |  |
Credit Derivatives [Line Items] |  |  |  |
Revenue volatility (percent) | 25.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |  | 25.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |
Average of probability of commercialization (percent) | 81.00%lgnd_FairValueInputsAverageOfProbabilityOfCommercialization / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |  | 68.00%lgnd_FairValueInputsAverageOfProbabilityOfCommercialization / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |
Sales beta (decimal) | 0.60lgnd_FairValueInputsSalesBeta / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |  | 0.60lgnd_FairValueInputsSalesBeta / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |
Credit rating (non-numeric) | B |  | BBB |
Equity risk premium (percent) | 6.00%us-gaap_FairValueInputsControlPremium / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |  | 6.00%us-gaap_FairValueInputsControlPremium / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember |
Minimum | Contingent Consideration |  |  |  |
Credit Derivatives [Line Items] |  |  |  |
Range of annual revenue subject to revenue sharing | 17.2lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember / us-gaap_RangeAxis = us-gaap_MinimumMember | [1] | 4.2lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember / us-gaap_RangeAxis = us-gaap_MinimumMember | [1]
Maximum | Contingent Consideration |  |  |  |
Credit Derivatives [Line Items] |  |  |  |
Range of annual revenue subject to revenue sharing | 17.3lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember / us-gaap_RangeAxis = us-gaap_MaximumMember | [1] | 19.8lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing / us-gaap_BusinessAcquisitionAxis = lgnd_CydexPharmaceuticalsIncMember / us-gaap_FairValueByLiabilityClassAxis = us-gaap_ContingentConsiderationClassifiedAsEquityMember / us-gaap_RangeAxis = us-gaap_MaximumMember | [1]
[1] | Revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement.

X
- Definition Amount of revenue for contingent consideration. + References No definition available. + Details
Name: | lgnd_AmountOfRevenueForContingentConsideration
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair Value Inputs, Annual Revenue Subject To Revenue Sharing + References No definition available. + Details
Name: | lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Average Probability of Commercialization + References No definition available. + Details
Name: | lgnd_FairValueInputsAverageOfProbabilityOfCommercialization
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Inputs, Credit Rating + References No definition available. + Details
Name: | lgnd_FairValueInputsCreditRating
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Inputs, Sales Beta + References No definition available. + Details
Name: | lgnd_FairValueInputsSalesBeta
Namespace Prefix: | lgnd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CreditDerivativesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage above fair value that an investor seeking to acquire control of an entity will pay, used as an input to measure fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsControlPremium
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration